-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK (LSE:GSK) Just Gave Investors Something To Think About

Simply Wall St·11/19/2026 06:14:59
Listen to the news

GSK (LSE:GSK) stock is back in focus after the US FDA granted accelerated approval for Nelkarmi, a targeted therapy for certain previously treated ALK positive non small cell lung cancer patients.

GSK shares, now at £18.58, have been relatively steady this year with a 1.45% year to date share price return, while investors who held on longer have seen a 47.97% total shareholder return over three years and 46.00% over five years, helped by dividends. Recent oncology approvals like Nelkarmi and updates to vaccines such as Bexsero feed into that longer record and help explain why the one year total shareholder return of 8.58% sits ahead of the more muted 90 day share price move, where the stock has drifted 3.25% lower as the market weighs new growth prospects against ongoing risks.

See how GSK compares with other large healthcare players by checking the hand picked list of solid balance sheet and fundamentals (8 results) that may also be weathering market swings with resilient fundamentals.

For GSK, a steady share price, fresh oncology approvals and a mixed recent return profile set up a simple question: Does the current valuation still pay investors enough for the risks on the table?

Most Popular Narrative: 14% Undervalued

GSK shares closed at £18.58, while the analyst consensus Narrative on Simply Wall St anchors fair value at about £21.73. This points to a material valuation gap that hinges on how the late stage pipeline and cost savings plan play out.

The main thing that has to go right is that GSK converts its enlarged late stage pipeline, particularly in oncology and long acting HIV and liver disease programs, into commercially meaningful products while delivering the planned £1.9b annual cost savings by 2029.

The current valuation implies investors are not fully crediting GSK for its stated >£40b 2031 sales outlook and the potential upside from oncology and long acting injectables. This is why this narrative describes the stock as undervalued and bullish.

See why 232 investors see GSK as 14% undervalued.

Result: Fair Value of £21.73 (UNDERVALUED)

Still, the GSK story can change quickly if loss of exclusivity in HIV bites harder than expected, or if pipeline setbacks repeat the camlipixant disappointment.

Find out about the key risks to this GSK narrative.

Next Steps

If this GSK story appears finely balanced between potential and risk, consider reviewing it while the data is fresh and pressure test it yourself using 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond GSK?

Do not stop with one stock. Use this window of time to line up a few strong candidates so the next opportunity does not pass you by.

  • Target reliable cash generators by scanning companies with strong payouts using 5 dividend fortresses that could help anchor the income side of your portfolio.
  • Hunt for potential mispricings through the 14 high quality undervalued stocks where solid fundamentals may not yet be fully reflected in current market quotes.
  • Stack the odds toward resilience by filtering for companies with robust finances via the 7 resilient stocks with low risk scores that keep volatility in tighter check.